Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898258 | 1.00 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| Methylene Chloride SCHEMBL28081516 | 0.88 | POLB (0.53) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| SCHEMBL28054665 | 0.87 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| SCHEMBL6899788 | 0.85 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| SCHEMBL1467517 | 0.85 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| SCHEMBL3141725 | 0.85 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| SCHEMBL135177 | 0.85 | L3MBTL1 (0.58) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| SCHEMBL47049 | 0.85 | L3MBTL1 (0.58) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| SCHEMBL3576321 | 0.85 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| SCHEMBL133363 | 0.85 | L3MBTL1 (0.58) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135818-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3470415-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-04-17 | — | — | EP | disclosed |
| CN-109641908-A | Five-ring heterocycles simultaneously [3,4-d] pyridazinone compound, preparation method, pharmaceutical composition and its application | 中国科学院上海药物研究所 | 2019-04-16 | — | — | CN | disclosed |
| CN-107417687-A | Five-ring heterocycles simultaneously [3,4 d] pyridazinone compound, its preparation method, pharmaceutical composition and its application | 中国科学院上海药物研究所 | 2017-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135818-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | FGFR1, FGFR3, FGFR4 | HSD17B10 289/4885SMN1; SMN2 2313/4885ALDH1A1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.